Condition

Locally Advanced Breast Carcinoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 15 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials15

Recruiting3

Common interventions25

Lead sponsors shown7

Clinical trials

15 shown

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast CancerNCT07137416 · 2026-10-05

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 TrialNCT06999798 · 2025-08-29

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or MelanomaNCT03941756 · 2018-08-14

Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast CancerNCT05547347 · 2023-03-21

Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast CancerNCT05945290 · 2022-07-07

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsNCT04550494 · 2021-04-26

ACTIVE_NOT_RECRUITING

SHAPE Neoadjuvant Chemotherapy ResponseNCT04715958 · 2021-04-19

ACTIVE_NOT_RECRUITING

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerNCT04498520 · 2021-03-31

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE StudyNCT04445844 · 2020-07-13

ACTIVE_NOT_RECRUITING

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerNCT04249167 · 2020-01-23

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerNCT03101748 · 2018-02-19

Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine TherapyNCT03281902 · 2017-11-13

ACTIVE_NOT_RECRUITING

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticNCT02115282 · 2014-03-29

ACTIVE_NOT_RECRUITING

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast CancerNCT01463072 · 2012-06-19

ACTIVE_NOT_RECRUITING

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast CancerNCT01149083 · 2010-06-30

Common interventions

Leading sponsors

Mayo Clinic 5 National Cancer Institute (NCI) 4 M.D. Anderson Cancer Center 2 City of Hope Medical Center 1 Kibo Nam 1 Mridula George, MD 1 Pamela Munster 1

Trial status mix

ACTIVE_NOT_RECRUITING6

RECRUITING3

COMPLETED2

WITHDRAWN2

SUSPENDED1

TERMINATED1

Phase mix

PHASE26

PHASE14

PHASE32

EARLY_PHASE11

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.